The one‐carbon metabolic enzyme MTHFD2 promotes resection and homologous recombination after ionizing radiation
Molecular Oncology · 27.03.2024
DOI: 10.1002/1878-0261.13645 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 27.03.2024. Verfasst von Petra Marttila und 14 weiteren Autor:innen. Beteiligte Einrichtung: Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden. Hauptthemen laut MEDLINE: Methylenetetrahydrofolate Dehydrogenase (NADP), Radiation, Ionizing, Homologous Recombination, Multifunctional Enzymes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Swedish Research Council, Swedish Cancer Society, The Erasmus+ programme of the European Union.
Abstract (Originalsprache)
The one‐carbon metabolism enzyme bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase 2 (MTHFD2) is among the most overexpressed proteins across tumors and is widely recognized as a promising anticancer target. While MTHFD2 is mainly described as a mitochondrial protein, a new nuclear function is emerging. Here, we observe that nuclear MTHFD2 protein levels and association with chromatin increase following ionizing radiation (IR) in an ataxia telangiectasia mutated (ATM)‐ and DNA‐dependent protein kinase (DNA‐PK)‐dependent manner. Furthermore, repair of IR‐induced DNA double‐strand breaks (DSBs) is delayed upon MTHFD2 knockdown, suggesting a role for MTHFD2 in DSB repair. In support of this, we observe impaired recruitment of replication protein A (RPA), reduced resection, decreased IR‐induced DNA repair protein RAD51 homolog 1 (RAD51) levels and impaired homologous recombination (HR) activity in MTHFD2 ‐depleted cells following IR. In conclusion, we identify a key role for MTHFD2 in HR repair and describe an interdependency between MTHFD2 and HR proficiency that could potentially be exploited for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
- One-carbon Therapeutics AB, Stockholm, Sweden.
- Weston Park Cancer Centre, Department of Oncology and Metabolism, The Medical School, University of Sheffield, UK.
ORCID-Profile: Petra Marttila, Korbinian Schelzig, Oliver Mortusewicz, Thomas Helleday
Förderung
- The Swedish Research Council
- Swedish Cancer Society
- The Erasmus+ programme of the European Union
- The Swedish Cancer Society Radiation Biology Programme
- Swedish Childhood Cancer Fund
- The Helleday Foundation
- The Swedish Innovation Agency
- Karolinska Institute's KID-funding for Doctoral Students
Zitieren
APA
Marttila, P., Bonagas, N., Chalkiadaki, C., Stigsdotter, H., Schelzig, K., Shen, J., Farhat, C. M., Hondema, A., Albers, J., Wiita, E., Rasti, A., Warpman Berglund, U., Slipicevic, A., Mortusewicz, O., & Helleday, T. (2024). The one‐carbon metabolic enzyme MTHFD2 promotes resection and homologous recombination after ionizing radiation. Molecular Oncology. https://doi.org/10.1002/1878-0261.13645
Vancouver
Marttila P, Bonagas N, Chalkiadaki C, Stigsdotter H, Schelzig K, Shen J, et al. The one‐carbon metabolic enzyme MTHFD2 promotes resection and homologous recombination after ionizing radiation. Molecular Oncology. 2024. doi:10.1002/1878-0261.13645
BibTeX
@article{Marttila2024,
author = {Marttila, Petra and Bonagas, Nadilly and Chalkiadaki, Christina and Stigsdotter, Hannah and Schelzig, Korbinian and Shen, Jianyu and Farhat, Crystal M and Hondema, Amber and Albers, Julian and Wiita, Elisée and Rasti, Azita and Warpman Berglund, Ulrika and Slipicevic, Ana and Mortusewicz, Oliver and Helleday, Thomas},
title = {The one‐carbon metabolic enzyme MTHFD2 promotes resection and homologous recombination after ionizing radiation},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13645}
}
EUVIMED